Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term...

Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...

Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...

Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian...